title: Twelve-dose drug regimen now also an option for preventing tuberculosis in children and adolescents.
authors.affiliation: The Children's Hospital at Westmead, Sydney, Australia2Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.
authors.forename: Ben J
authors.initials: BJ
authors.lastname: Marais
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D055985:Latent Tuberculosis / Q000517:prevention & control*; D008297:Male; D012293:Rifampin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine